• First exosome product in-market, EXO-NET customer base growing across US, Europe and Asia
• Ovarian cancer screening test delivered outstanding 94% diagnostic accuracy
• CAR-T and CAR-NK exosome therapies achieved in vitro anti-cancer efficacy in breast cancer cells
• neuCA15-3 breast cancer monitoring test showed high disease specificity

INOVIQ has made significant progress during the half-year to 31 December 2024, proving its technology and getting product to market. The Company grew its EXO-NET customer base and delivered key development milestones across its exosome diagnostic and therapeutic programs. The exosome diagnostic for screening ovarian cancer delivered outstanding accuracy, the CAR-NK-exosome therapeutic achieved in vitro anti-cancer efficacy in breast cancer cells, and the neuCA15-3 breast cancer monitoring test showed disease specificity. These results validate INOVIQ's technology and substantially de-risk its diagnostic and therapeutic pipeline for breast and ovarian cancers. Key highlights include the first EXO-NET product in-market with a growing customer base, the ovarian cancer screening test delivering 94% accuracy, the achievement of CAR-T and CAR-NK exosome Proof-of-Concept for killing breast cancer cells, and the disease-specific testing completed for the neuCA15-3 breast cancer monitoring test. The company also further validated its NEURO-NET technology for isolating brain-derived exosomes in Parkinson's Disease.